Vivozon's Oral Non-Narcotic Analgesic Candidate Receives European Patent Registration Approval

Vivozon has received a notice of patent registration approval for its oral non-narcotic analgesic candidate, accelerating its commercialization efforts.

On May 14, Vivozon announced that it had received a patent registration approval notice from the European Patent Office (EPO) for "VVZ-2471." This indicates that the European patent examination process has essentially reached its final stage.

This patent covers a dual antagonist technology that simultaneously inhibits metabotropic glutamate receptor 5 (mGluR5) and serotonin receptor 2A (5-HT2A). Vivozon has secured exclusive rights to VVZ-2471 and its core compound group in all major global markets, including the United States, China, Taiwan, Japan, and now Europe.

Global clinical trials for VVZ-2471 are progressing smoothly. The Phase 2 clinical trial for patients with postherpetic neuralgia (PHN) currently underway in Korea recently completed all patient dosing and has now entered the data analysis phase. The company plans to use this clinical trial to secure efficacy and safety data and to lay the groundwork for developing a future global late-stage clinical strategy.

In the United States, an investigator-initiated trial (IIT) is underway in collaboration with leading local research institutions, based on Investigational New Drug (IND) approval. Vivozon aims to explore the possibility of expanding indications through the U.S. trial, while also building up clinical data in the world’s largest pharmaceutical market to strengthen its global commercialization competitiveness.

VVZ-2471 is an oral non-narcotic analgesic candidate being developed based on a mechanism that simultaneously modulates key receptors involved in pain signal transmission. It is being developed as a first-in-class drug designed to avoid the addiction and tolerance issues inherent to conventional opioid analgesics.

A Vivozon official stated, “The European patent registration decision is further recognition of the technological uniqueness and global intellectual property competitiveness of VVZ-2471,” adding, “With the completion of dosing for the domestic Phase 2 trial and the ongoing investigator-initiated trial in the United States, discussions on technology transfer and commercialization with global pharmaceutical companies are expected to accelerate.”

This content was produced with the assistance of AI translation services.